A preliminary study of the cytotoxicity of the protein extract of *Chrysobalanus icaco* L. and *Eugenia astringens* Cambess., commercialized in markets

Thaís A. Pedrete^{1a*}, Julianderson O.S. Carmo², Emiliano O. Barreto², Josino C. Moreira¹

¹Center for Studies on Workers' Health and Human Ecology, National School of Public Health – Oswaldo Cruz Foundation, Rio de Janeiro, RJ, 21041-210, Brazil.

²Institute of Biological Sciences and Health – Federal University of Alagoas, Maceió, AL, 57072-900, Brazil.

Abstract

The use of plants and their products for medical treatment is very common procedure in Brazil, especially for treatment of diabetes. In fact, several plants can demonstrate hypoglycemic effects in vitro assays. However, the use for human treatment requires the knowledge of their toxicological properties. The aim of this study was to evaluate the effect of protein extracts of *Chrysobalanus icaco* collected from natural habitats and of *Eugenia astringens* acquired from the market of Rio de Janeiro on the viability and migration of fibroblasts. *E. astringens* has a similar morphology as *C. icaco* and it is sold as *Chrysobalanus* in a popular market in Rio de Janeiro. Being a different plant, *E. astringens* expresses different proteins, and its protein extract has proved to possess higher toxic properties than *C. icaco* does. Cytotoxicity assays indicated that, as the protein extract concentration increases, fibroblast viability decreases. Only the *E. astringens* extract displayed cytotoxicity at all concentrations, in addition to reduced fibroblast migration. The results obtained in this study demonstrates that it's necessary integrative policies for rational use of medicinal plants and their commercialization, since the current use of medicinal plants may be inadequate and it is of great importance for Public Health.

Keywords

Cytotoxicity; Protein extract; Hypoglycemic plant; *Chrysobalanus icaco*; *Eugenia astringens*; popular markets

Abbreviations: MAD, Mercado de Madureira; PG, Praia Grande; RMA, Restinga de Massambaba; AL, Marechal Deodoro; MTT, 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

^aPresent address: Department of Physiological Sciences, Institute of Biology Roberto Alcântara Gomes – State University of Rio de Janeiro (UERJ), Rio de Janeiro, RJ, 20550-170, Brazil.

*Corresponding author: tha.pedrete@gmail.com (Thaís A. Pedrete)

1. Introduction

Several plants are widely used for medical purposes by the population, but this use is most often made from a lay indication, without knowing the risks of toxic effects. Besides, there is no guarantee of the provenance and proper storage of these supposedly “medicinal plants”. It is clear that there is a lack of incentive and scientifically-based information to integrative and complementary practices and actions to promote the safe and rational use of medicinal plants, including information on how the species should be prepared and used by the population (Bochner *et al.*, 2012).

The leaf extract (tea) of the plant *Chrysobalanus icaco* L., a species of restinga popularly known as abajerú, is used in folk medicine because it exerts biological activities, such as the decrease of blood sugar levels, being indicated for the treatment of diabetes, besides be diuretic and antioxidant (Venancio *et al.*, 2018). Another plant (*Eugenia astringens*, Cambess.) which is morphologically similar to *C. icaco*, also is known by the same popular name of abajerú and is commercialized as *C icaco* (Bochner *et al.*, 2012; Silva and Peixoto, 2009). These two species may not possess the same therapeutic and toxicological properties, which are of concern to Public Health. The attribution of hypoglycemic activity to *E. astringens* may indicate a misconception since other species of Myrtaceae have hypoglycemic potential (Silva and Peixoto, 2009). So, in order to clarify the toxicological aspects of the extract obtained from these 2 plants, a cytotoxic assay was performed.

For cytotoxicity studies in animal cells several techniques, using distinct cell types as a target, are available. Cytotoxicity means the determination of any toxic effects at the cellular level, such as changes in membrane permeability, cell death or enzymatic inhibition resulted from exposure to a toxicant, in this case, the studied plants or plant products (Stockert *et al.*, 2012).

Cell viability can be evaluated by several methods, among which the one which involves the conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan by mitochondrial reactivation in active-living cells (Zandi *et al.*, 2016). The MTT assay is a standard colorimetric assay that estimates the cytotoxic potential of the samples, in addition to measuring the cellular proliferation of drug agents. Cell viability is expressed as a percentage of live cells from the tested material, comparing with the percentage of cells of the cytotoxicity positive control (Stockert *et al.*, 2018).

Another test to evaluate the toxicity of the plant extract is the Scratch Wound Healing Assay, which allows measuring the migration of cells that is a phenomenon present in the healing process. It is a method in which a crack imitates a wound in a monolayer of confluent cells so that the cells at the edge gradually move towards the crack (Manoj *et al.*, 2009). Wound healing is the process of repairing and regenerating the dermis and epidermis that accompanies the lesions (Liang *et al.*, 2007; Pitz *et al.*, 2016). The evaluation of the healing activity of plant extracts is scarce at the cellular level. Fibroblast cultures have been proposed as a method for the investigation of wound healing activity, since these cells are the main source of extracellular connective tissue matrix and the migration of fibroblasts is considered vital for rapid and effective skin repair damaged (Manoj *et al.*, 2009).

The lack of data about the toxicity of the protein extract of these 2 plants commercialized as abajerú (*C. icaco* and *E. astringens*), protein extracts of *Chrysobalanus icaco* collected directly from its natural habitats and of *Eugenia astringens* acquired from the market of Rio de Janeiro was performed using the viability and migration of fibroblasts assay.

2. Material and methods

2.1 Plant sampling

Chrysobalanus icaco leaves were collected directly from its natural habitats, Praia Grande – Arraial do Cabo- RJ (PG; -22,9696606, -42,0302859), Restinga de Massambaba – RJ (RMA; -22,9337727, -42,4267012), Marechal Deodoro – AL (AL; -9,7823233, -35,852364), as shown in the map (Fig. 1). *Eugenia astringens* leaves were purchased on the market Mercado de Madureira located in the North zone of Rio de Janeiro city.

Fig. 1. Sampling sites. AL - Marechal Deodoro, MAD – Mercadão de Madureira, RMA - Restinga de Massambaba, PG - Praia Grande (PG).

2.1 Protein extraction

About 10 mg of each lyophilized sample were weighed into microtubes in triplicate. Samples were incubated in the presence of 400 μ l lysis buffer (4% SDS 0.1 M Tris-HCl buffer pH 7.6) at 95 °C for 15 min in a thermomixer. The lysate extract was frozen at -80 °C for further quantification of total proteins by the Lowry method (Lowry et al., 1951), using bovine serum albumin (2.0 mg/mL) as the standard for the analytical curve. Samples (2 μ L) and analytical curve (0, 10, 20, 30, 40, 50, 60 and 70 μ g/mL) were read in a Jasco V-530 spectrophotometer at the wavelength of 750 nm.

2.2 Cytotoxicity evaluation of protein extracts

This assay was performed as follows:

2.2.1 Cell culture

Fibroblasts (3T3 cell line) were kept in medium Dulbecco's Modified Eagle Medium (DMEM), containing 10 % fetal bovine serum, L-glutamine (2 mM) and gentamicin (40 μ g/mL) in incubator at 37 °C and 5 % CO₂.

2.2.1.1 Cell viability assay

119 The effect of the protein extracts of *Eugenia astringens* (Mercadão de
120 Madureira) and *Chrysobalanus icaco* (Restinga de Massambaba - RJ, Marechal - AL,
121 Praia Grande - RJ) on fibroblasts viability was evaluated through the MTT assay
122 (Mosmann, 1983).

123 The cells were seeded in a 96 well plates and placed in CO₂ incubator overnight.
124 The cells were then treated with different sample solutions (1, 5, 10 and 20 µg/mL) in
125 four replicates. The control group was treated only with the medium (DMEM). After
126 treatment, a solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
127 bromide) (5 mg/mL in phosphate buffered saline - 1X PBS pH 7.4) was added to each
128 well and incubated for 4 hours. Subsequently, the supernatant was discarded and 150 µl
129 of dimethyl sulfoxide were added for solubilization of the formazan crystals. The
130 absorbance was measured using a microplate spectrophotometer (DTX 880 Multimode
131 Detector, Beckman Coulter), adjusted to 595 nm, and the optical density was calculated
132 (Equation 1).

133

134 Equation 1 – Optical density of cells submitted to the cell viability assay.

135

$$A = \frac{DO_t}{DO_{nt}} \times 100$$

136

DO_t – optical density of treated cells

137

DO_{nt} – optical density of non-treated cells

138

139 2.2.1.2 Scratch wound healing assay

140

141 The effect of the protein extracts of *Eugenia astringens* (Mercadão de
142 Madureira), *Chrysobalanus icaco* (Restinga de Massambaba - RJ, Marechal - AL, Praia
143 Grande - RJ - branch) on fibroblast migration was evaluated through cell migration
144 technique, method described by Liang *et al.* (2007).

145 Cells (7 x 10⁴ cells / well, measured by the Newbauer's chamber) were seeded in
146 24-well plates and maintained overnight for cell adhesion and formation of a monolayer
147 at approximately 80% confluency. A small part of the monolayer was removed in the
148 middle of the plate with a 200 µL pipette tip (a scratch is placed on the monolayer and
149 the part removed is discarded). Cells were washed with phosphate buffered saline and
150 treated with 5 µg/mL of the samples or culture medium (control) in triplicate. This
151 exposure concentration at which some effects started to be observed in the cell viability
152 assay was chosen to perform the present assay. Cell migration was assessed by
153 photomicrographs at 0- and 24-hours post-exposure using an inverted microscope

(Olympus IX70) with digital camera to measure the area of wound closure. The photomicrographs were analyzed using Image J software and cell migration was expressed as the area in pixels, so that the percentage of closure of the initial area formed was determined quantitatively (Equation 2).

158

Equation 2 – Migration rate of fibroblasts submitted to the cell migration assay.

$$\% \text{ migration} = \frac{(A_0 - A_t)}{A_0} \times 100$$

160

A_0 – original area (time = 0 h)

162

A_t – area after the scratch (time = 24 h).

163

2.4 Statistical analysis

165

The results of the cell viability and migration tests were expressed as mean $\pm$ standard error, performed in triplicate and analyzed statistically using analysis of variance (ANOVA), followed by Newman-Keuls post-test. The results were considered significant when $p < 0.05$. All results were analyzed using GraphPad Prism® software version 5.01 (GraphPad Software Inc, San Diego CA, USA).

171

3. Results

173

3.1 Plant identification and protein concentration

175

The identification of the studied plants was performed by a botanist from the Jardim Botânico do Rio de Janeiro. The plant purchased on the market (Mercadão de Madureira) was identified as *Eugenia astringens* Cambess., of family Myrtaceae, and the plants collected in Marechal Deodoro, Massambaba and Praia Grande as *Chrysobalanus icaco* L., plant from family Chrysobalanaceae.

181

Chrysobalanaceae can be morphologically differentiated from the Brazilian Myrtaceae species, by some characteristics, such as phyllotaxia, which is alternating (and opposite in Myrtaceae). Nevertheless, the similar form of the leaves of *C. icaco* and *E. astringens* can cause confusion (Fig. 2), the *E. astringens* leaf has a fold around it facing the abaxial part (Fig. 2c) not found in *C. icaco*.

186

Fig. 2. Comparison between the branches of *Chrysobalanus icaco* L. (Chrysobalanaceae) (a) and *Eugenia astringens* Cambess (Myrtaceae) (b). Abaxial part of *E. astringens* leaf (c). Source: Photos by the author.

This misconception has been previously reported (Bochner *et al.*, 2012; Silva and Peixoto, 2009), claiming that the trade of medicinal plants is not a safe source of sale, as it may be difficult for both the trader and the consumer to correctly identify a desirable plant. And yet there is the problem that different plants known by the same popular name are commercialized without proof of their pharmacological properties and toxicological safety (Bochner *et al.*, 2012), besides the adulteration possibilities. Unfortunately, in Brazil, the supervision of trade of medicinal plants by regulatory agencies is still incipient.

Total protein concentrations ranged from 30.18 to 54.95 $\mu\text{g } \mu\text{L}^{-1}$ in *Eugenia astringens*, from 28.01 to 43.88 $\mu\text{g } \mu\text{L}^{-1}$ in *Chrysobalanus icaco*.

3.2 Cytotoxicity evaluation of protein extracts

Fibroblasts (3T3 cell line) were submitted to the cell viability assay, exposed to different concentrations of protein extract and to the cell migration assay, exposed to a determined concentration of this extract.

3.2.1 Cell viability assay

To evaluate the effects of extracts of *E. astringens* (MAD), *C. icaco* (RMA), *C. icaco* (AL) and *C. icaco* (PG) on fibroblast viability, the MTT assay was performed.

213 The results for the cell viability assay are shown in Fig. 3, in which it can be
214 observed and compared the reduction of fibroblasts viability among the species and
215 protein extract concentration.

216 Treatment with *E. astringens* (MAD) at all concentrations tested, reduced cell
217 viability, decreasing by 8.8% (1 µg/mL), 19.2% (5 µg/mL), 23% (10 µg/mL) and 17%
218 (20 µg/mL) the percentage of viable cells. Exposure with *C. icaco* (RMA) at
219 concentrations of 1, 5 and 10 µg/mL did not alter significantly the fibroblasts viability.
220 On the other hand, the increase in concentration resulted in a decrease in the percentage
221 of viable cells, leading to a reduction of 22.4% (P <0.001) in cell viability when the
222 highest concentration (20 µg/mL) was used. Treatment with *C. icaco* (AL), in turn,
223 induced a decrease in cell viability (8-16 %) at all concentrations tested, when compared
224 to the control group. In addition, treatment with *C. icaco* (PG) at 1 µg/mL did not alter
225 the viability of fibroblasts, whereas treatment with the other concentrations induced a
226 decrease in cell viability (12-14 %).

227

228

Fig. 3. Effect of protein extracts of *Eugenia astringens* and *Chrysobalanus icaco* on fibroblasts viability. MAD – Mercado de Madureira, RMA - Restinga de Massambaba, AL - Marechal Deodoro, PG - Praia Grande (PG). The dashed line represents the control group (100 %). The circle indicates high reduction on fibroblast viability for *E. astringens* treatment. Results are mean $\pm$ S.E.M. n = 4.

3.2.2 Scratch wound healing assay

To evaluate the effects of extracts of *E. astringens* (MAD), *C. icaco* (RMA), *C. icaco* (AL) and *C. icaco* (PG) on fibroblast migration, the cell migration assay (Scratch Wound Healing Assay) was performed.

As shown in Figure 4, treatment with *C. icaco* (RMA), *C. icaco* (AL) and *C. icaco* (PG) was not able to alter the migration rate of fibroblasts. On the other hand, it can be noted that the treatment with *E. astringens* led to a significant reduction in the migration of these cells by 26.04% ($p < 0.05$), comparing to the control.

The migration of fibroblast is illustrated in Fig. 5, in which can be observed a lower migration of these cells when treated with *E. astringens* protein extract than the *C. icaco* treatments, slowing wound closure.

Fig. 4. Effect of the extracts of *Eugenia astringens* and *Chrysobalanus icaco* on the migration of fibroblasts at times 0 and 24 hours. MAD – Mercado de Madureira, RMA - Restinga de Massambaba, AL - Marechal Deodoro, PG - Praia Grande (PG). Circle indicates significant reduction on fibroblast migration for *E. astringens* treatment. Results are mean $\pm$ S.E.M. One-way Anova, followed by Newman-Keuls post-test, * $p < 0.05$. n = 3.

Fig. 5. Effect of the extracts of *Eugenia astringens* and *Chrysobalanus icaco* on the migration of fibroblasts (3T3) at 0 h and 24 hours. MAD – Mercado de Madureira, RMA – Restinga de Massambaba, AL – Marechal Deodoro, PG - Praia Grande. Circle indicates significant reduction on fibroblast migration for *E. astringens* treatment. n=3.

4. Discussion

There is a misunderstanding regarding the sale of abajerú in Mercado de Madureira, where *Eugenia astringens*, of the same popular name, is sold in place of *Chrysobalanus icaco*. This is of great concern to Public Health, because *C. icaco* is popularly used as medicinal plant for treating diabetes, due to its hypoglycemic potential. Meanwhile the population consumes tea from the leaves of *E. astringens*, coming from these markets instead of *C. icaco*. Medicinal plants are widely used due to their easy accessibility, but they usually not have their efficacy and safety well established (Bochner *et al.*, 2012). This fact can become a risk to those who use them since they can cause more deleterious effects than bring health benefits. It is of prime importance to inspect qualified individuals, traders, distributors and producers for regularization of the sale of medicinal plants.

Silva and Peixoto (2009) raised three hypotheses regarding the introduction of *Eugenia astringens*, replacing *Chrysobalanus icaco* in popular marketing. First, it would be a strategy of the merchants to circumvent the competent oversight, by having the same popular name, but neither could it distinguish. A second hypothesis would be related to the difficulty in the recognition of the species by the collectors and sellers, as well as the consumers, due to the similar morphology. The last hypothesis would be the attribution of hypoglycemic activity to *E. astringens* by herbivores, since other species of Myrtaceae, such as pitanga (*Eugenia uniflora* L.), jambo (*Eugenia jambos* L.) and *Eucalyptus*, are used by the population for this purpose and have antioxidant, antifungal

283 and antibacterial properties (Queiroz *et al.*, 2015). Also, the natural environments to
 284 which *C. icaco* occurs are restinga-type vegetation sites, which are usually areas of
 285 environmental protection, which makes it difficult to collect specimens of this species.
 286 Therefore, this could also be a hypothesis regarding the introduction of *E. astringens*,
 287 replacing *C. icaco* in popular marketing. This species is not hypoglycemic like *C. icaco*,
 288 which can lead to intoxication in those people who buy erroneously, thinking that they
 289 are acquiring the correct abajerú plant.

290 Since medicinal plants may also have unknown toxicological properties, the
 291 evaluation of toxicity, through in vitro tests, is required. Cytotoxicity of the extracts of
 292 medicinal plants, including those that are hypoglycemic, can affect cellular processes
 293 like healing that is crucial for diabetic patients. Hyperglycemia alters leukocyte
 294 function, increasing the risk of bleeding and impairing inflammatory and healing
 295 processes (Negri, 2005; Aquino *et al.*, 2019). This difficulty in healing occurs due to
 296 cardiovascular complications, which cause blockage or decrease of blood circulation,
 297 and due to excess glucose, which can impair the functioning of the immune system.
 298 That is, diseased vessels decrease blood flow, especially to the legs and feet, harming
 299 the healing process and high glycemic levels incapacitate the body's defense cells (Hu *et al.*, 2002).

301 Zandi *et al.* (2016) verified the viability of fibroblasts (ovine line) in extracts of
 302 different plants (*Aloe vera*, hena, camomile, licorice, myrtle, mint, cinnamon, ginger
 303 and cedar) and that at the minimum concentration (6.25 µg/mL), the viability of dermal
 304 fibroblasts by MTT assay increased significantly in cedar ($p < 0.05$). Combination of
 305 *Aloe vera*, mint extract and licorice significantly increased the viability of dermal
 306 fibroblasts ($p < 0.05$). *Aloe vera*, which is also known for its hypoglycemic activity, has
 307 the ability to stimulate proliferation of L929 fibroblasts (Manoj *et al.*, 2009). Calloni *et al.* (2016) tested the phenolic extract of *Plinia trunciflora* from the same family as *E. astringens* on human lung fibroblast cells in the presence and absence of amiodarone, a drug used to treat arrhythmia, but which causes toxicity in the lungs. The extract rich in polyphenols was able to prevent the decrease of cellular viability (MTT test) and the ATP biosynthesis.

313 There are no studies testing the viability of fibroblasts exposed to protein
 314 extracts of *Chrysobalanus icaco*, but ethanolic extracts of these species prove to be
 315 important in cellular processes. Silva *et al.* (2017) evaluated the antifungal activity of
 316 the *C. icaco* ethanolic extract, noting the inhibition of growth of *Candida albicans* and

317 *C. parapsilosis*, strains exposed to this extract.

318 Pitz *et al.* (2016) evaluated the in vitro activity of ethanolic extract of *Plinia*
 319 *peruviana* bark, the same family as the *E. astringens*, in healing processes and
 320 antioxidant activity in urinary fibroblasts (L929 cell line). The cell migration assay
 321 (Scratch Wound Healing Assay) indicated that none of the tested shell concentrations
 322 (0.5, 5, 25, 50 and 100 µg/ml) was able to increase the migration rate after 12 hours of
 323 incubation. These results demonstrate a positive effect of the peel on the wound healing
 324 process in the L929 fibroblast cell line, probably due to the antioxidant activity
 325 exhibited by phytochemicals in the extract. Manoj *et al.* (2009) verified the effect of
 326 germplasm of *Aloe vera*, which is also hypoglycemic in L929 fibroblasts, through the
 327 cell migration assay, confirming the increase in fibroblast migration, which is important
 328 for regeneration and skin repair in case of injury.

329 There are no studies testing the viability and migration of fibroblasts exposed to
 330 protein extracts of *C. icaco* and *E. astringens*, however ethanolic extracts are used in
 331 studies to test toxicity of *Eugenia* species. The in vitro antioxidant activity of the
 332 ethanolic extract of *Eugenia uniflora* was determined by the inhibition of spontaneous
 333 autoxidation in brain homogenate, with the LD₅₀ of 5.93 g/kg in mice (Auricchio *et al.*,
 334 2007). In the phytotoxicity test of the *Eugenia catharinae* extract, it was observed that
 335 ethyl acetate and hexane fractions inhibited seed germination, while the hexane fraction
 336 showed higher inhibition of lettuce seedlings. *E. catharinae* demonstrated a
 337 considerable toxic activity, encouraging the search for the compounds responsible for
 338 this activity (Colla and Brighente, 2011).

339

340 **Conclusion**

341

342 The assays to evaluate the toxicity of the protein extracts of the plants studied
 343 served to make aware of the sale and use of the *Eugenia astringens* plant, sold in place
 344 of *Chrysobalanus icaco*, since it reduced cell viability at all concentrations of the extract
 345 and decreased the fibroblast migration rate. These results showed that *E. astringens* can
 346 cause cytotoxic effects if consumed in larger doses.

347 The present work demonstrated the importance of research in the area of Public
 348 Health and the dissemination and communication to society of the results of scientific
 349 works since, due to the confounding of the use of medicinal plants, diabetic patients
 350 may opt for natural products in therapeutic use for the treatment of diabetes, in the

351 wrong way.

352

353 **Acknowledgements**

354

355 The authors are thankful to CNPq, to CAPES and to Dra. Viviane Kruehl from the
356 Research Institute of Botanical Garden of Rio de Janeiro for the identification of the
357 specimens collected. The cytotoxicity assays were performed at the Laboratory of Cell
358 Biology of the Federal University of Alagoas under the supervision of Dr. Emiliano
359 Barreto. This study was carried out with financial support from the Coordination and
360 Improvement of Higher Level or Education Personnel – CAPES (PhD's grant).

361

362 **References**

363

364 Aquino, J.A., Baldoni, A.O., Oliveira, C.L., Cardoso, C.S., Figueiredo, R.C., Sanches, C.
365 2019. Pharmacotherapeutic empowerment and its effectiveness in glycemic control in
366 patients with Diabetes Mellitus. *Diabetes Metab. Syndr.: Clinical Research & Reviews*
367 **13** (1), 137-142.

368 Auricchio, M.T., Bugno, A., Barros, S.B.M., Bacchi, E.M. 2007. Atividades
369 antimicrobiana e antioxidante e toxicidade de *Eugenia uniflora*. *Lat. Am. J. Pharm.*, 26
370 (1), 76-81.

371 Bochner, R., Fiszon, J.T., Assis, M.A., Avelar, K.E.S. 2012. Problemas associados ao
372 uso de plantas medicinais comercializadas no Mercado de Madureira, município do
373 Rio de Janeiro, Brasil. *Revista Brasileira Plantas Mediciniais* **14** (3), 537–547.

374 Calloni, C., Silva-Santos, L.F., Martínez, L.S., Salvador, M. 2016. Data in brief data on
375 cell viability of human lung fibroblasts treated with polyphenols-rich extract from
376 *Plinia*. *Data in Brief* **6**, 728–731.

377 Colla, G., Brighente, I.M.C. 2011. Potencial tóxico dos extratos de *Eugenia catharinae*.
378 In: 51º Congresso Brasileiro de Química, 7 (136).

379 Hu, F.B., Stamper, M.J., Haffner, S.M., Solomon, C.G., Willett, W.C., Manson, J.E.
380 2002. Elevated risk of cardiovascular disease of type 2 diabetes. *Diabetes Care* **25**,
381 1129-1134.

382 Liang, C., Park, A.Y., Guan, J. 2007. In vitro scratch assay: a convenient and
383 inexpensive method for analysis of cell migration in vitro. *Nature Protocols* **2** (2), 329–
384 333.

385 Manoj, K., Mishra, D., Maity, T.K., Gupta, S.D. 2009. Screening wound-healing
386 potential of different *Aloe vera* L. germplasms at the cellular level. *Medicinal and*
387 *Aromatic Plant Science and Biotechnology* **3** (1), 2–4.

388 Moosa, A., Farzand, A., Sahi, T.S., Khan, S.A. 2017. Transgenic expression of

antifungal pathogenesis-related proteins against phytopathogenic fungi – 15 years of
success. Israel Journal of Plant Science, doi: 10.1080/07929978.2017.1288407.

Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival:
Application to proliferation and cytotoxicity assays. Journal of Immunology Methods
65 (1), 55–63.

Negri, G. 2005. Diabetes melito: plantas e princípios ativos naturais hipoglicemiantes.
Revista Brasileira Ciências Farmacêuticas **41** (2), 121–142.

Pitz, H.S., Pereira, A., Blasius, M.B., Voytena, A.P.L., Affonso, R.C.L., Fanan, S.,
Trevisan, A.C.D., Ribeiro-do-Valle, R.M., Maraschin, M. 2016. In vitro evaluation of
the antioxidant activity and wound healing properties of jaboticaba (*Plinia peruviana*)
fruit peel hydroalcoholic extract. Oxidative Medicine and Cellular Longevity **3**, 1-6.

Queiroz, J.M.G., Suzuki, M.C.M., Motta, A.P.R., Nogueira, J.M.R., Carvalho, E.M.
2015. Aspectos populares e científicos do uso de espécies de *Eugenia* como fitoterápico.
Revista Fitos **9** (2), 73-159.

Santos, K.M., Gomes, I.N.F., Silva-Oliveira, R.J., Pinto, F.E., Oliveira, B.G., Chagas,
R.C.R., Romão, W., Reis, R.M.V., Ribeiro, R.I.M.A. 2018. *Bauhinia variegata* candida
fraction induces tumor cell death by activation of caspase-3, RIP, and TNF-R1 and
inhibits cell migration and invasion in vitro. BioMed Research International **2018**, 1–10.

Sharma, S.S., Dietz, K. 2006. The significance of amino acids and amino acid-derived
molecules in plant responses and adaptation to heavy metal stress. Journal of
Experimental Botany **57** (4), 711–726.

Sharma, S.S., Dietz, K. 2008. The relationship between metal toxicity and cellular redox
imbalance. Cell Press **14** (1), 43–50.

Silva, I.M., Peixoto, A.L. 2009. O abajurú (*Chrysobalanus icaco* L. e *Eugenia*
rotundifolia Casar.) comercializado na cidade do Rio de Janeiro, Brasil. Brazilian
Journal of Pharmacognosy **19** (1b), 325–332.

Silva, J., Peres, A.R., Paixão, T.P., Silva, A.S., Baetas, A.C., Barbosa, W.L., Monteiro,
M.C., Andrade, M.A. 2017. Antifungal activity of hydroalcoholic extract of
Chrysobalanus icaco against oral clinical isolates of *Candida* species. Pharmacognosy
Research **9** (1), 96–100.

Stockert, J.C., Blázquez-Castro, A., Cañete, M., Horobin, R.W., Villanueva, A. 2012.
MTT assay for cell viability: Intracellular localization of the formazan product is in
lipid droplets. Acta Histochemica **114** (8), 785–796.

Stockert, J.C., Horobin, R.W., Colombo, L.L., Blázquez-Castro, A. 2018. Tetrazolium
salts and formazan products in cell biology: Viability assessment, fluorescence imaging,
and labeling perspectives. Acta Histochemica **120** (3), 159–167.

Venancio, V.P., Almeida, M.R., Antunes, L.M.G. 2018. *Cocoplum* (*Chrysobalanus icaco*
L.) decreases doxorubicin-induced DNA damage and downregulates Gadd45a, Il-1 β ,
and Tnf- α in vivo. Food Research International **105**, 996–1002.

428 White, P.A.S., Araújo, J.M., Cercato, L.M., Souza, L.A., Barbosa, A.P., Quintans-Junior,
 429 L.J., Machado, U.F., Camargo, E.A., Brito, L.C., Santos, M.R. 2016. *Chrysobalanus*
 430 *icaco* L. leaves normalizes insulin sensitivity and blood glucose and inhibits weight gain
 431 in high-fat diet-induced obese mice. *Journal of Medicinal Food* **19** (2), 155–160.

432 Zandi, M., Masoumian, M., Shariatnia, A., Sanjabi, M.R. 2016. Optimal concentrations
 433 and synergistic effects of some herbal extracts on viability of dermal fibroblasts. *Gene*
 434 *Cell Tissue* **3** (4), 1–7.

435

436

Alagoas

Marechal Deodoro (AL)

Rio de Janeiro

Mercadão de Madureira (MAD) - Market

Restinga de Massambaba (RMA)

Praia Grande (PG)

Eugenia astringens - MAD

Chrysobalanus icaco - RMA

Chrysobalanus icaco - AL

Chrysobalanus icaco - PG

Control

***E. astringens* - MAD**

***C. icaco* - RMA**

***C. icaco* - AL**

***C. icaco* - PG**

0h

24h